Active substanceDimethyloxobutylphosphonyl dimethylateDimethyloxobutylphosphonyl dimethylate
Similar drugsTo uncover
  • Dimephosphone®
    solution inwards externally 
  • Dimephosphone®
    concentrate in / in 
  • Dosage form: & nbspSolution for oral and external use.
    Composition:
    Composition per 100 ml:
    Active substance: dimethyloxobutylphosphonyl dimethylate - 15 g.
    Excipients: purified water - up to 100 ml.

    Description:
    Colorless or yellowish, transparent or opalescent liquid with a peculiar smell.
    Pharmacotherapeutic group:Anti-acid drug.
    ATX: & nbsp

    V.03.A.X   Other medications

    Pharmacodynamics:
    Dimefosfon shows anti-acid, membrane-stabilizing, anti-inflammatory and antioxidant properties, normalizes blood flow and metabolism of brain tissues, reduces cardiac and pulmonary insufficiency, improves blood circulation regulation, including cerebral circulation.
    The anti-acid effect is realized due to the intensification of renal and pulmonary mechanisms of regulation of the acid-base state, enhancement of intraorganic blood flow and tissue metabolism, and dimefosfon reduces the content of lactic and pyruvic acids in the brain tissues.
    Dimefosfon stabilizes the cell membranes, restoring the reactivity of the cerebral vessels, improving the functions of the cerebral hemispheres and brainstem, decreasing the depth of consciousness disturbances, restoring the sleep-wake cycle, reflexes, arcs closing through the stem divisions, reducing the pyramidal, cerebellar, vestibular, visual and auditory disorders.
    Antioxidant action is carried out by preventing the activation of lipid peroxidation and increasing the activity of antioxidant enzymes in the brain tissues.
    Dimefosfon strengthens the energy processes in the brain as directly, directly affecting the mitochondria, and indirectly by stimulating the pituitary-thyroid system, increasing the consumption of thyroid hormones by tissues, which is accompanied by activation of energy and catabolic processes in the mitochondria of cells. It shows the properties of some neurotransmitters. (GABA-positive, H-cholino and dopaminergic activity).
    Dimefosfon reduces cardiac and pulmonary insufficiency, restoring the resistivity of peripheral vessels (arterial and venous).
    Dimefosfon improves the regulation of cerebral circulation, not having a pronounced vasodilating effect, but it positively affects the metabolism of brain tissues during their ischemia, improves venous outflow. The effectiveness of clinical use of the drug for various forms of cerebrovascular insufficiency is associated with its ability to increase the resistance of nerve cells to ischemia, with a decrease in edema and, in connection with this, improvement in microcirculation.
    When topical application dimefosfon has anti-inflammatory and antiseptic effect, increases the protective functions of the skin and mucous membranes.
    Pharmacokinetics:Dimephosphone after a single dose is absorbed quite full, easily penetrates through the histohematological barriers and is distributed to various organs and tissues, with the maximum concentration (Cmax) in the blood observed within the first hour after the administration of the drug; Three hours after administration, the maximum concentrations are determined in the brain, heart and spleen. Three days after the single administration of Dimefosfon, only trace concentrations remain in the body.Dimefosfon is excreted unchanged mainly with urine in the amount of 11-15% of the drug (up to 70% of the withdrawn amount of the drug is released within the first 12 hours). With feces no more than 0.5% is output.
    Indications:
    Inside, as part of complex therapy:
    Acute and chronic disorders of cerebral circulation, the consequences of ischemic and hemorrhagic strokes, craniocerebral and neurosurgical injuries, planned neurosurgical operations, osteochondrosis, multiple sclerosis, chronic non-specific lung diseases with signs of respiratory and pulmonary heart failure (dimephosphone application does not relieve asthma attacks and does not affect the frequency of use of aerosols of beta-adrenomimetics), vegetative-vascular dystonia by parasympathetic type, chronic cerebrospinal fluid rovascular insufficiency due to atherosclerosis and hypertension, migraine, Meniere's disease, respiratory diseases, acidosis, atopic bronchial asthma and pollinosis.
    Outwardly:
    Infectious-inflammatory-allergic diseases of the skin and mucous membranes: wounds,the area of ​​the seams and the exit point of Ilizarov's spokes; erysipelas inflammations; in dermatology - complex treatment of skin diseases (acne, oily seborrhea, rosacea); prevention of radiation mucositis.
    Contraindications:
    - Epilepsy;

    - Chronic renal failure 2-3 degrees (creatinine clearance less than 40 ml / min);

    - Children and adolescents under 18 years of age (due to the lack of clinical data on its use in this category of patients) in acute and chronic disorders of cerebral circulation, the consequences of ischemic and hemorrhagic strokes, craniocerebral and neurosurgical trauma, planned neurosurgical operations, osteochondrosis, multiple sclerosis , chronic nonspecific lung diseases with signs of respiratory and pulmonary-cardiac failure, chronic cerebrovascular insufficiency due to atherosclerosis eroza and hypertension, migraine, Meniere's disease;

    - Children under 12 years of age with vegetative-vascular dystonia according to the parasympathetic type.
    Carefully:Dimefosfon well tolerated by patients. When applied to mucous membranes can cause irritation, in this case it is necessary to dilute dimefosfona solution in half.
    Pregnancy and lactation:
    Currently, data on the use of the drug in pregnancy is not enough to evaluate the teratogenic effect of Dimefosfona.
    In view of this, Dimefosfon should be administered during pregnancy and during breastfeeding only if the intended benefit from its use exceeds the potential risk to the fetus or infant.
    Studies in animals have not revealed a damaging effect on the embryo and its development.
    Dosing and Administration:
    Inside dimefosfon apply after eating, washing down with water.
    The course of treatment depends on the nature of the disease and lasts from 3 days to 2 months.
    In the complex therapy of the following diseases and conditions:
    With acute and chronic disturbance of cerebral circulation, the consequences of ischemic and hemorrhagic strokes, craniocerebral and neurosurgical trauma adults 15 ml (1 tablespoon) 3-4 times a day. The course duration is 2-3 weeks, in some cases up to 6 weeks.

    With planned neurosurgical operations 15 ml (1 tablespoon) for 5 days before and 2 months after the operation.

    With osteochondrosis adults 10 ml (1 dessert spoon) 3-4 times a day for 2-3 weeks, improvement is observed on the 8-10 day of treatment.

    With multiple sclerosis Adults 100 mg / kg (45 ml) per day - 15 ml (1 tablespoon) 3 times a day for 10 days in the autumn-spring period every month.

    In chronic nonspecific lung diseases with signs of respiratory and pulmonary heart failure adults 15 ml (1 tablespoon) 3-4 times a day. Course - 7-10 days. The use of dimephosphone does not relieve asthma attacks and does not affect the frequency of use of beta-adrenomimetic aerosols.

    With vegetative-vascular dystonia according to the parasympathetic type adults 15 ml (1 tablespoon) 3 times a day for 2-3 weeks, children over 12 years at 50 mg / kg (10-15 ml) 3 times a day for 3 weeks.

    With chronic cerebrovascular insufficiency due to atherosclerosis and hypertension 15 ml (1 tablespoon) 3 times a day for 2- 3 weeks.

    With migraine 15 ml (1 tablespoon) 3 times a day for 2-3 weeks.

    With Meniere's disease 15 ml (1 tablespoon) 3 times a day for 3 weeks.

    With diseases of the respiratory system, acidosis, atonic bronchial asthma and pollinosis adults are prescribed 15-25 ml each, children are prescribed 15-25 ml, children are prescribed 75-100 mg / kg: children under 3 years old - 5 ml (1 teaspoon), 3-8 years - 10 ml (1 dessert spoon), over 8 years old - 15 ml (1 tablespoon) 3 times a day,at a heavy current - 4 times a day for 4-5 weeks.

    With atonic bronchial asthma in combination with pollinosis appoint 2-3 weeks before the onset of impairment and take during the entire flowering period. For dosing, you can use a measuring cup, enclosed in a package.

    Outwardly

    When infectious-inflammatory-allergic diseases of the skin and mucous membranes in the form of dressings, turundas and lotions with a solution daily for

    3-14 days.

    In the complex treatment of acne wipe the skin 3-4 once a day, in the evening - lotion.

    At the face - lubricate the inflammation zone 3 times a day for 3-5 days.

    On the area of ​​seams and places of exit of spokes Ilizarov impose daily gauze napkins impregnated with dimephosphone in for 7-14 days.

    For prevention of radial mucositis -gauze wipes, moistened dimefosbackground, fit in the projection of the beams 20 minutes before exposure dose.

    Side effects:
    Dyspeptic phenomena, drowsiness and worsening of concentration (on the 3-4th day of taking the drug pass).
    Overdose:Increased severity of dose-dependent side effects. Treatment - gastric lavage, Activated carbon, symptomatic therapy.
    Interaction:During the release of dimefosfona interactions with other drugs have not been identified.
    Special instructions:
    At occurrence of drowsiness in the first days of reception of a preparation it is necessary to refrain from driving of motor transport and employment demanding the raised attention and high speed of psychomotor reactions.
    It has a bitter taste. Children are recommended to drink milk, fruit juice, sweet tea.
    Form release / dosage:
    Solution for oral and external use 15%.
    Packaging:
    100 ml or 200 ml in bottles of orange or brown glass. A bottle together with a measuring cup and instruction for use is placed in a pack of cardboard.
    Storage conditions:In a dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.
    Shelf life:3 years. Do not use after the expiry date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:LS-002620
    Date of registration:29.12.2011
    The owner of the registration certificate:TATHIMFARMPREPARATY, JSC TATHIMFARMPREPARATY, JSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp25.01.2016
    Illustrated instructions
      Instructions
      Up